

Q1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

15 patients with a new diagnosis of multiple myeloma were treated between 1st January 2023 and 30th June 2023,

Q2. Of the multiple myeloma patients over the past 6 month, how many were treated with the following:

- **Belantamab Mafodotin [Blenrep]**
- **Bortezomib [Velcade] monotherapy or with dexamethasone**
- **Bortezomib, thalidomide and dexamethasone [VTD]**
- **Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)**
- **Carfilzomib [Kyprolis] and dexamethasone**
- **Carfilzomib [Kyprolis], Lenalidomide [Revlmid] and dexamethasone**
- **Daratumumab [Darzalex] monotherapy**
- **Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)**
- **Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)**
- **Elranatamab**
- **Idecabtagene vicleucel [Abecma]**
- **Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)**
- **Ixazomib [Ninlaro], Lenalidomide [Revlmid] and dexamethasone (known as IRd)**
- **Lenalidomide [Revlmid] monotherapy**
- **Lenalidomide [Revlmid] and dexamethasone**
- **Pomalidomide [Imnovid] and dexamethasone**
- **Selinexor and dexamethasone**
- **Talquetamab**
- **Teclistamab [Tecvayli]**
- **Any other systemic anti-cancer therapy**

The Health Board is unable to provide information on the number of patients treated or which patients were treated for Multiple Myeloma or for any of the combined listed regimes, however, please find below the quantities dispensed, across Health Board pharmacies for the period January 2023 – June 2023.

Drug	Quantity
BELANTAMAB MAFODOTIN (BLENREP) (CU) 100 mg Intravenous Infusion 1 Vial Pack	48
BORTEZOMIB 1.45 mg in 0.58mL Subcutaneous Injection 1 Syringe Pack	7
BORTEZOMIB 1.8 mg in 0.72mL Subcutaneous Injection 1 Syringe Pack	3
BORTEZOMIB 2 mg in 0.8mL Subcutaneous Injection 1 Syringe Pack	83
BORTEZOMIB 2.25 mg in 0.9mL Subcutaneous Injection 1 Syringe Pack	158
BORTEZOMIB 2.5 mg in 1mL Subcutaneous Injection 1 Syringe Pack	163
BORTEZOMIB 2.75 mg in 1.1mL Subcutaneous Injection 1 Syringe Pack	66
BORTEZOMIB 3 mg in 1.2mL Subcutaneous Injection 1 Syringe Pack	30
BORTEZOMIB 3.25 mg in 1.3mL Subcutaneous Injection 1 Syringe Pack	7
BORTEZOMIB 3.5 mg Injection 1 Vial Pack	3
CARFILZOMIB 10 mg Intravenous Infusion 1 Vial Pack	195
CARFILZOMIB 30 mg Intravenous Infusion 1 Vial Pack	140
CARFILZOMIB 60 mg Intravenous Infusion 1 Vial Pack	190
CYCLOPHOSPHAMIDE 50 mg Tablets 100 Tablet Pack	23
DARATUMUMAB 1800 mg in 15mL Subcutaneous Injection 1 Vial Pack	291
DEXAMETHASONE 2 mg Soluble Tablets 50 Tablet Pack	4
DEXAMETHASONE 2 mg Tablets 50 Tablet Pack	592
DEXAMETHASONE 500 micrograms Tablets 30 Tablet Pack	3
ISATUXIMAB 100 mg in 5mL Intravenous Injection 1 Vial Pack	343
ISATUXIMAB 500 mg in 25mL Intravenous Injection 1 Vial Pack	129
IXAZOMIB 3 mg Capsules 3 Capsule Pack	7
IXAZOMIB 4 mg Capsules 3 Capsule Pack	39
LENALIDOMIDE (MYLAN) 10 mg Capsules 21 Capsule Pack	41
LENALIDOMIDE (MYLAN) 15 mg Capsules 21 Capsule Pack	13
LENALIDOMIDE (MYLAN) 2.5 mg Capsules 21 Capsule Pack	3

Drug	Quantity
LENALIDOMIDE (MYLAN) 20 mg Capsules 21 Capsule Pack	10
LENALIDOMIDE (MYLAN) 25 mg Capsules 21 Capsule Pack	3
LENALIDOMIDE (MYLAN) 5 mg Capsules 21 Capsule Pack	16
LENALIDOMIDE (MYLAN) 7.5 mg Capsules 21 Capsule Pack	6
LENALIDOMIDE (REVLIMID) 15 mg Capsules 21 Capsule Pack	52
LENALIDOMIDE (REVLIMID) 20 mg Capsules 21 Capsule Pack	24
LENALIDOMIDE (REVLIMID) 25 mg Capsules 21 Capsule Pack	10
POMALIDOMIDE 3 mg Capsules 21 Capsule Pack	23
POMALIDOMIDE 4 mg Capsules 21 Capsule Pack	53
PREDNISOLONE 5 mg Tablets 28 Tablet Pack	453
PREDNISOLONE 5 mg Tablets 28 Tablet Pre-Pack	382
THALIDOMIDE 50 mg Capsules 28 Capsule Pack	61